Targeting Cdk11 in osteosarcoma cells using the CRISPR‐cas9 system

Osteosarcoma is the most common type primary malignant tumor of bone. Patients with regional osteosarcoma are routinely treated with surgery and chemotherapy. In addition, many patients with metastatic or recurrent osteosarcoma show poor prognosis with current chemotherapy agents. Therefore, it is important to improve the general condition and the overall survival rate of patients with osteosarcoma by identifying novel therapeutic strategies. Recent studies have revealed that CDK11 is essential in osteosarcoma cell growth and survival by inhibiting CDK11 mRNA expression with RNAi. Here, we apply the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)‐Cas9 system, a robust and highly efficient novel genome editing tool, to determine the effect of targeting endogenous CDK11 gene at the DNA level in osteosarcoma cell lines. We show that CDK11 can be efficiently silenced by CRISPR‐Cas9. Inhibition of CDK11 is associated with decreased cell proliferation and viability, and induces cell death in osteosarcoma cell lines KHOS and U‐2OS. Furthermore, the migration and invasion activities are also markedly reduced by CDK11 knockout. These results demonstrate that CRISPR‐Cas9 system is a useful tool for the modification of endogenous CDK11 gene expression, and CRISPR‐Cas9 targeted CDK11 knockout may be a promising therapeutic regimen for the treatment of osteosarcoma. © 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:199–207, 2015.

[1]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[2]  R. Gorlick,et al.  Osteosarcoma: a review of diagnosis, management, and treatment strategies. , 2010, Clinical advances in hematology & oncology : H&O.

[3]  Quan Tian,et al.  Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells , 2010, Investigational New Drugs.

[4]  Xin Zhang,et al.  Targeted mutagenesis in rice using CRISPR-Cas system , 2013, Cell Research.

[5]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[6]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.

[7]  S. T. Kim,et al.  CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11p110 , 2014, Oncogene.

[8]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[9]  X. Zi,et al.  Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma , 2010, Molecular Cancer Therapeutics.

[10]  P. Picci,et al.  CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity , 2007, Oncogene.

[11]  Guang-Yuh Chiou,et al.  Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy. , 2012, Current gene therapy.

[12]  F. Zhang,et al.  CRISPR/Cas9 for genome editing: progress, implications and challenges. , 2014, Human molecular genetics.

[13]  Inder M. Verma,et al.  Gene therapy: trials and tribulations , 2000, Nature Reviews Genetics.

[14]  R. Barrangou,et al.  CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. , 2011, Annual review of genetics.

[15]  Yarden Katz,et al.  Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system , 2013, Cell Research.

[16]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[17]  Q. Kan,et al.  Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. , 2014, Cancer letters.

[18]  P. Loyer,et al.  Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors , 2008, Journal of Biological Chemistry.

[19]  S. Kumta,et al.  Alendronate regulates cell invasion and MMP‐2 secretion in human osteosarcoma cell lines , 2004, Pediatric blood & cancer.

[20]  Martin J. Aryee,et al.  Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing , 2014, Nature Biotechnology.

[21]  Josée Dostie,et al.  Repurposing CRISPR/Cas9 for in situ functional assays , 2013, Genes & development.

[22]  H. van Bakel,et al.  Cdk11-cyclinL controls the assembly of the RNA polymerase II mediator complex. , 2012, Cell reports.

[23]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[24]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[25]  K. Ryan,et al.  The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy , 2011, Autophagy.

[26]  Chad A. Cowan,et al.  Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. , 2013, Cell stem cell.

[27]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[28]  P. Lollini,et al.  CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity , 2014, Oncogene.

[29]  A. Inoue,et al.  Failure To Proliferate and Mitotic Arrest of CDK11p110/p58-Null Mutant Mice at the Blastocyst Stage of Embryonic Cell Development , 2004, Molecular and Cellular Biology.

[30]  H. Mankin,et al.  MicroRNA‐1 (miR‐1) inhibits chordoma cell migration and invasion by targeting slug , 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[31]  P. Lollini,et al.  CD99 acts as an oncosuppressor in osteosarcoma. , 2006, Molecular biology of the cell.

[32]  Yoshio Koyanagi,et al.  Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus , 2013, Scientific Reports.

[33]  M. Kimura,et al.  Generation of an ICF Syndrome Model by Efficient Genome Editing of Human Induced Pluripotent Stem Cells Using the CRISPR System , 2013, International journal of molecular sciences.

[34]  Young-Chae Chang,et al.  Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. , 2007, Journal of biochemistry and molecular biology.

[35]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[36]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[37]  Chenguang Wang,et al.  Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. , 2010, Cancer research.

[38]  George A. Calin,et al.  RNA interference in the clinic: challenges and future directions , 2011, Nature Reviews Cancer.

[39]  D. Campana,et al.  PITSLRE protein kinase activity is associated with apoptosis , 1995, Molecular and cellular biology.

[40]  M. Boutros,et al.  A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis , 2014, The EMBO journal.

[41]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[42]  W. El-Deiry,et al.  CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth , 2013, Cell cycle.

[43]  N. Gray,et al.  Systematic Kinome shRNA Screening Identifies CDK11 (PITSLRE) Kinase Expression Is Critical for Osteosarcoma Cell Growth and Proliferation , 2012, Clinical Cancer Research.

[44]  S. Jung,et al.  Risedronate inhibits human osteosarcoma cell invasion , 2009, Journal of experimental & clinical cancer research : CR.

[45]  Huitu Liu,et al.  Cellular and molecular evidence for malignancy-inhibitory functions of p15RS , 2012, Cell cycle.

[46]  A. Montag,et al.  Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.

[47]  T. Ishida,et al.  Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis , 2004, Clinical & Experimental Metastasis.

[48]  M. Nelson,et al.  Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90. , 2004, The Biochemical journal.

[49]  J. Wang,et al.  Downregulation of p57kip2 promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells , 2011, Journal of cellular biochemistry.